ProQR TherapeuticsPRQR
About: ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
Employees: 157
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
375% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 8
271% more capital invested
Capital invested by funds: $31.7M [Q3] → $118M (+$86M) [Q4]
183% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 6
82% more call options, than puts
Call options by funds: $296K | Put options by funds: $163K
62% more funds holding
Funds holding: 47 [Q3] → 76 (+29) [Q4]
33.61% more ownership
Funds ownership: 21.36% [Q3] → 54.96% (+33.61%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Chardan Capital Keay Nakae 14% 1-year accuracy 10 / 73 met price target | 160%upside $4 | Buy Maintained | 14 Mar 2025 |
HC Wainwright & Co. Andrew Fein 29% 1-year accuracy 102 / 354 met price target | 679%upside $12 | Buy Maintained | 14 Mar 2025 |
Jones Trading Catherine Novack 11% 1-year accuracy 1 / 9 met price target | 614%upside $11 | Buy Initiated | 12 Feb 2025 |
Financial journalist opinion









